# EDGAR Filing Document

**Accession Number:** 0001512717
**File Stem:** 0001193125-25-297751
**Filing Date:** 2025-11
**Character Count:** 2873
**Document Hash:** e7346bd21fc32fde6e5e30bebdacd32b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-297751.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001193125-25-297751

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251125

**EFFECTIVENESS DATE**: 20251126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Theratechnologies Inc.
- **CENTRAL INDEX KEY:** 0001512717
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A8
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35203
- **FILM NUMBER:** 251523175

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2015 PEEL STREET
- **STREET 2:** 11TH FLOOR
- **CITY:** MONTREAL
- **PROVINCE COUNTRY:** A8
- **BUSINESS PHONE:** 1 438-858-3967

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2015 PEEL STREET
- **STREET 2:** 11TH FLOOR
- **CITY:** MONTREAL
- **PROVINCE COUNTRY:** A8

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-35203** 

**Theratechnologies Inc.** 

**(Translation of registrant's name into English)** 

**2015 Peel Street, Suite 1100** 

**Montreal, Quebec** 

**H3A 1T8, Canada** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Ordinary Shares, no par value per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒  |
|  Rule 12g-4(a)(2) | ☐  |
|  Rule 12h-3(b)(1)(i) | ☒  |
|  Rule 12h-3(b)(1)(ii) | ☐  |
|  Rule 15d-6 | ☐  |
|  Rule 15d-22(b) | ☐  |

---

Approximate number of holders of record as of the certification or notice date: One (1) holder

------

Pursuant to the requirements of the Securities Exchange Act of 1934, Theratechnologies Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: November 25, 2025 | **Theratechnologies Inc.** | **Theratechnologies Inc.** |
|  | By: | */s/ David Risk* |
|  | Name: | David Risk |
|  | Title: | Operating Chairman |

---